NovoCure CEO Asaf Danziger to Retire, CFO Ashley Cordova Named Successor
Published on 09/03/2024 at 08:07, updated on 09/03/2024 at 08:08
Share
Share
Insiders
![Asaf Danziger](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Currently, Asaf Danziger occupies the position of Chief Executive Officer & Director at NovoCure Ltd. and Co-Managing Director at NovoCure GmbH (a subsidiary of NovoCure Ltd.). In the past Mr. Danziger occupied the position of Chief Executive Officer of Cybro Medical Ltd. and Communications & Electronics Officer at Israel Defense Forces. He received an undergraduate degree from Ben-Gurion University of the Negev.
View full profile| Linked companies | |
|---|---|
NovoCure GmbH
 NovoCure GmbH Pharmaceuticals: MajorHealth Technology Part of NovoCure Ltd., NovoCure GmbH is an oncology company based in Munich, Germany. NovoCure is pioneering a novel therapy for solid tumors called Tumor Treating Fields, or TTFields. Asaf Danziger has been the CEO of the German company since 2012. | Chief Executive Officer |
Palliser's Smith On Activist Investing in Japan
May 30, 2025 at 08:58 am EDT MT
Berkshire doubles Constellation stake, sells Citigroup and other financial stocks
May 16, 2025 at 07:23 am EDT RE
Novo Nordisk ousts CEO after falling behind in weight loss market
May 16, 2025 at 02:46 pm EDT RE
Novo Nordisk ousts CEO after falling behind in weight loss market
May 16, 2025 at 01:18 pm EDT RE
Rio Ousted Chief Jakob Stausholm To Seek Boss With More Mining Experience - FT
May 23, 2025 at 04:03 am EDT RE
Activist hedge fund Parvus builds stake in Novo Nordisk, FT reports
June 09, 2025 at 02:14 pm EDT RE
UK's Wood Group chair plans exit pending strategic clarity
More news
May 23, 2025 at 07:13 am EDT RE
- Stock Market
- Insiders
- Asaf Danziger
- NovoCure CEO Asaf Danziger to Retire, CFO Ashley Cordova Named Successor
